Zai Lab Acquires China Rights to TESARO's PARP Inhibitor

Zai Lab of Shanghai formed a collaboration with Boston-based TESARO for China development of TESARO's niraparib, a clinical-stage oral PARP inhibitor. Zai will own China rights to niraparib, though development will be guided by a joint committee and TESARO has an option to participate in China commercialization. In addition, TESARO has an option to license two novel discovery-stage immuno-oncology programs from Zai Lab.Zai will make an upfront payment to TESARO, and TESARO will be eligible for milestone payments, both development and sales-related. More details.... Stock Symbol: (NSDQ: TSRO) Share this with colleagues: // //